Last reviewed · How we verify
PD-RBD
At a glance
| Generic name | PD-RBD |
|---|---|
| Sponsor | Beijing Friendship Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Parkinson's Disease Biomarker Study
- [18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
- Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
- Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
- Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD
- Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
- Parkinson's Disease Biomarkers in Nerve Cells in the Gut
- Neuro-immune Interactome in Parkinson's Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |